healthnews.com — Bayer has been given fifteen days by the FDA to take action regarding allegations that the company is marketing and selling two aspirin products that have not been given FDA approval. The company has been told to comply by either ending sales of their Bayer Aspirin with Heart Advantage and Bayer Women’s Low Dose Aspirin plus Calcium or to proceed with clinical trials, in order to gain the required FDA approval. The German company manufactures the Heart Advantage product, which is aspirin with a plant extract called phytosterois, that the company claims on the products label has been proven to help lower cholesterol, and Bayer’s Women’s Low Dose Aspirin, aspirin combined with calcium carbonate that the company states on the label helps to fight osteoporosis.
Add a live kick counter to your blog >>
You can even customize the image by choosing your own colors, and then clicking the button below to update the preview and the html code:
Simply copy and paste this HTML into your blog post.